The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting
Open accessAbstract
BACKGROUND: Patients' responses to oral antiplatelet therapy are subject to variation. Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy. METHODS: We randomly assigned 2440 patients scheduled for coronary stenting at 38 centers to a strategy of platelet-function monitoring, with drug adjustment in patients who had a poor response to antiplatelet therapy, or to a conventional strategy without monitoring and drug adjustment. The primary end point was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization 1 year after stent implantation. For patients in the monitoring group, the VerifyNow P2Y12 and aspirin point-of-care assays were used in the catheterization laboratory before stent implantation and in the outpatient clinic 2 to 4 weeks later. RESULTS: In the monitoring group, high platelet reactivity in patients taking clopidogrel (34.5% of patients) or aspirin (7.6%) led to the administration of an additional bolus of clopidogrel, prasugrel, or aspirin along with glycoprotein IIb/IIIa inhibitors during the procedure. The primary end point occurred in 34.6% of the patients in the monitoring group, as compared with 31.1% of those in the conventional-treatment group (hazard ratio, 1.13; 95% confidence interval [CI], 0.98 to 1.29; P=0.10). The main secondary end point, stent thrombosis or any urgent revascularization, occurred in 4.9% of the patients in the monitoring group and 4.6% of those in the conventional-treatment group (hazard ratio, 1.06; 95% CI, 0.74 to 1.52; P=0.77). The rate of major bleeding events did not differ significantly between groups. CONCLUSIONS: This study showed no significant improvements in clinical outcomes with platelet-function monitoring and treatment adjustment for coronary stenting, as compared with standard antiplatelet therapy without monitoring. (Funded by Allies in Cardiovascular Trials Initiatives and Organized Networks and others; ARCTIC ClinicalTrials.gov number, NCT00827411.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, large, superiority RCTs have failed to show a higher efficacy of routine platelet-function testing in guiding antiplatelet therapy post-PCI.322,322a”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [322]
In the citing paper
“Current evidence does not support platelet function testing to adjust DAPT.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [322]
In the citing paper
“Despite initial enthusiasm, multiple large, randomized studies have failed to show any clinical benefit when antithrombotic regimens are adjusted on the basis of platelet function testing.60–62”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citationGuidelines on myocardial revascularization
Wijns, W. C., Kolh, P. H., Danchin, N., Mario, C. D., Falk, V., Folliguet, T. A., Garg, S., Huber, K., James, S. K., Knuuti, J., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq277 · Cited by 3,228
Price, M. J. (2011) · JAMA · doi:10.1001/jama.2011.290 · Cited by 1,311
Lincoff, A. M., Bittl, J. A., Harrington, R. A., Feit, F., Kleiman, N. S., Jackman, J. D., Sarembock, I. J., Cohen, D. J., Spriggs, D. J., Ebrahimi, R., et al. (2003) · JAMA · doi:10.1001/jama.289.7.853 · Cited by 1,158
Bonello, L., Tantry, U. S., Marcucci, R., Blindt, R., Angiolillo, D. J., Becker, R. C., Bhatt, D. L., Cattaneo, M., Collet, J., Cuisset, T., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.047 · Cited by 1,151
Self-citationPrasugrel versus clopidogrel for acute coronary syndromes without revascularization
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874
Breet, N. J., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Ruven, H. J. T., Bal, E. T., Deneer, V. H. M., Harmsze, A. M., der Heyden, J. A. S. V., Rensing, B. J. W. M., et al. (2010) · JAMA · doi:10.1001/jama.2010.181 · Cited by 850
Mehta, S. R., Tanguay, J., Eikelboom, J. W., Jolly, S. S., Joyner, C. D., Granger, C. B., Faxon, D. P., Rupprecht, H., Budaj, A., Avezum, Á., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61088-4 · Cited by 812
Self-citationThrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., de Werf, F. V., White, H. D., Aylward, P. E., Wallentin, L. C., Chen, E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109719 · Cited by 756
Self-citationCannon, C. P., Harrington, R. A., James, S. K., Ardissino, D., Becker, R. C., Emanuelsson, H., Husted, S., Katus, H. A., Keltai, M., Khurmi, N. S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62191-7 · Cited by 665
Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis
Buonamici, P., Marcucci, R., Migliorini, A., Gensini, G. F., Santini, A., Paniccia, R., Moschi, G., Gori, A. M., Abbate, R., & Antoniucci, D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.094 · Cited by 655
Price, M. J., Endemann, S., Gollapudi, R. R., Valencia, R., Stinis, C. T., Levisay, J. P., Ernst, A., Sawhney, N. S., Schatz, R. A., & Teirstein, P. S. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn046 · Cited by 651
A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents
Babapulle, M. N., Joseph, L., Bélisle, P., Brophy, J. M., & Eisenberg, M. J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16850-5 · Cited by 645
Trenk, D., Stone, G. W., Gawaz, M., Kastrati, A., Angiolillo, D. J., Müller, U., Richardt, G., Jakubowski, J. A., & Neumann, F.-J. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.026 · Cited by 626
Hochholzer, W., Trenk, D., Bestehorn, H.-P., Fischer, B., Valina, C. M., Ferenc, M., Gick, M., Caputo, A., Büttner, H. J., & Neumann, F. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.065 · Cited by 587
Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention
Brar, S. S., ten Berg, J. M., Marcucci, R., Price, M. J., Valgimigli, M., Kim, H.-S., Patti, G., Breet, N. J., DiSciascio, G., Cuisset, T., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.059 · Cited by 423
Self-citationPlatelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention
Price, M. J., Angiolillo, D. J., Teirstein, P. S., Lillie, E. O., Manoukian, S. V., Berger, P. B., Tanguay, J., Cannon, C. P., & Topol, E. J. (2011) · Circulation · doi:10.1161/circulationaha.111.029165 · Cited by 396
Roberts, J. D., Wells, G. A., May, M. R. L., Labinaz, M. X., Glover, C. A., Froeschl, M. P. V., DICK, A. J., Marquis, J.-F., O’Brien, E. R., Gonçalves, S. C., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60161-5 · Cited by 393
Enoxaparin versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention
Montalescot, G., White, H. D., Gallo, R., Cohen, M. C., Steg, P. G., Aylward, P. E., Bode, C., Massimo Chiariello, A., King, S. B., Harrington, R. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052711 · Cited by 359
Self-citationValgimigli, M., Campo, G. C., Cesare, N. D., Meliga, E., Vranckx, P., Furgieri, A., Angiolillo, D. J., Sabaté, M., Hamon, M., Repetto, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.833236 · Cited by 225
Cuisset, T., Frère, C., Quilici, J., Morange, P., Mouret, J.-P., Bali, L., Moro, P.-J., Lambert, M., Alessi, M., & Bonnet, J. (2008) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2008.08.018 · Cited by 152
Self-citationSosnowski, C. (2008) · PubMed · Cited by 144
Aradi, D., Komócsi, A., Price, M. J., Cuisset, T., Arı, H., Hazarbasanov, D., Trenk, D., Sibbing, D., Valgimigli, M., & Bonello, L. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.05.100 · Cited by 141
Self-citationCollet, J., Cayla, G., Cuisset, T., Elhadad, S., Rangé, G., Vicaut, É., & Montalescot, G. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.09.029 · Cited by 92
Self-citationDose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose
Collet, J., Silvain, J., Landivier, A., Tanguy, M., Cayla, G., Bellemain-Appaix, A., Vignolles, N., Gallier, S., Beygui, F., Peña, A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.776757 · Cited by 87
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationKernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Self-citation2014 ESC/EACTS Guidelines on myocardial revascularization
Authors Task Force Members, Windecker, S., Kolh, P., Alfonso, F., Collet, J., Cremer, J., Falk, V., Filippatos, G., Hamm, C. W., Head, S. J., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,408
Self-citation2014 ESC/EACTS Guidelines on myocardial revascularization
Kolh, P. H., Windecker, S., Alfonso, F., Collet, J., Cremer, J., Falk, V., Filippatos, G. S., Hamm, C. W., Head, S. J., Jüni, P., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu366 · Cited by 4,217
Self-citation
Metadata
- Authors
- Collet, J.-P., Cuisset, T., Rangé, G., Cayla, G., Elhadad, S., Pouillot, C., Henry, P., Motreff, P., Carrié, D., Boueri, Z., Belle, L., Van Belle, E., Rousseau, H., Aubry, P., Monségu, J., Sabouret, P., O'Connor, S. A., Abtan, J., Kerneis, M., Saint-Etienne, C., Barthélémy, O., Beygui, F., Silvain, J., Vicaut, E., & Montalescot, G.
- Affiliations
- Pitié-Salpêtrière Hospital (FR)
- Hôpital de la Timone (FR)
- Les Hôpitaux de Chartres (FR)
- Centre Hospitalier Universitaire de Nîmes (FR)
- Hôpital Lariboisière (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Hôpital Rangueil (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- HIA du Val-de-Grâce à Paris (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-11-29
- Volume
- 367
- Issue
- 22
- Pages
- 2100-2109
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2145323902
- Cited by
- 887
- References
- 26
- Citations by year
- 2026: 15 · 2025: 20 · 2024: 22 · 2023: 31 · 2022: 31 · 2021: 47 · 2020: 44 · 2019: 52 · 2018: 72 · 2017: 77 · 2016: 80 · 2015: 123 · 2014: 122 · 2013: 141 · 2012: 8
- FWCI
- 81.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- antiplatelet therapy, coronary stenting, platelet function monitoring, VerifyNow P2Y12 assay, clopidogrel, prasugrel, aspirin, stent thrombosis, bleeding events, glycoprotein IIb/IIIa inhibitors, individualized dosing, major adverse cardiovascular events
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Coronary Disease, Coronary Thrombosis, Female, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Pyridines, Thiophenes, Ticlopidine, Stents, Drug Monitoring, Point-of-Care Systems, Retreatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
